Alexion
NEWS
The results published in the NEJM state that pegcetacoplan met the study’s primary endpoint for efficacy, demonstrating an advantage over eculizumab with a statistically significant improvement in adjusted means of 3.8 g/dL of hemoglobin at week 16 (p<0.001). An impressive 85% of patients were transfusion free at 16 weeks, in contrast to only 15% of eculizumab-treated patients.
The deal has been approved by both companies’ boards and is expected to close in the third quarter of 2021.
Although October doesn’t appear to be a very busy month for the U.S. Food and Drug Administration’s PDUFA dates, there are a few. Here’s a look at the next two weeks.
In October 2019, Alexion Pharmaceuticals snapped up Achillon Pharmaceuticals and its oral small molecule Factor D inhibitor program for a rare kidney disease for $930 million in cash. This week, the company shuttered the program following disappointing clinical data.
Alexion said the acquisition of Portola will bolster its commercial portfolio and create long-term value for its shareholders.
It was a very busy week for clinical trial news. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 7, 2020.
The company has abandoned the project based on unfavorable early-stage data.
There were plenty of clinical trial announcements this week. Here’s a look.
JOBS
IN THE PRESS